Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab ; volume:24 ; number:6 ; day:2 ; month:5 ; year:2024 ; pages:550-562 ; date:6.2024
Cardiovascular toxicology ; 24, Heft 6 (2.5.2024), 550-562, 6.2024
- Urheber
-
Bergamini, Corinna
Niro, Lorenzo
Springhetti, Paolo
Ferri, Luisa
Trento, Laura
Minnucci, Ilaria
Maffeis, Caterina
Tafciu, Elvin
Rossi, Andrea
Fiorio, Elena
Benfari, Giovanni
Ribichini, Flavio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12012-024-09861-6
- URN
-
urn:nbn:de:101:1-2407291147161.821488451253
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bergamini, Corinna
- Niro, Lorenzo
- Springhetti, Paolo
- Ferri, Luisa
- Trento, Laura
- Minnucci, Ilaria
- Maffeis, Caterina
- Tafciu, Elvin
- Rossi, Andrea
- Fiorio, Elena
- Benfari, Giovanni
- Ribichini, Flavio
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
Late cardiotoxicity related to HER2-targeted cancer therapy
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
Late cardiotoxicity related to HER2-targeted cancer therapy
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
Late cardiotoxicity related to HER2-targeted cancer therapy
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management